Cargando…

Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System

The majority of neutralizing antibodies (NAbs) against SARS-CoV-2 recognize the receptor-binding domain (RBD) of the spike (S) protein. As an escaping strategy, the RBD of the virus is highly variable, evolving mutations to thwart a natural immune response or vaccination. Targeting non-RBD regions o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wenping, Wang, Fulian, Li, Yu, Yan, Lei, Liu, Lili, Zhu, Wei, Ma, Peixiang, Shi, Xiaojie, Yang, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143083/ https://www.ncbi.nlm.nih.gov/pubmed/37112683 http://dx.doi.org/10.3390/vaccines11040771

Ejemplares similares

Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago
por: Qiang, Min, et al.
Publicado: (2021)

Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD
por: Peter, Antonia Sophia, et al.
Publicado: (2022)

Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein
por: Otsubo, Ryota, et al.
Publicado: (2022)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

Potently neutralizing and protective human antibodies against SARS-CoV-2
por: Zost, Seth J., et al.
Publicado: (2020)

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
por: Amanat, Fatima, et al.
Publicado: (2021)

Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
por: Stefan, Maxwell A., et al.
Publicado: (2021)

Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD
por: Wang, Nianshuang, et al.
Publicado: (2019)

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
por: Shan, Sisi, et al.
Publicado: (2021)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
por: Xiaojie, Shi, et al.
Publicado: (2021)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
por: Pan, Yongbing, et al.
Publicado: (2021)

The NTD Supply Chain Forum—Strengthening the backbone of NTD programs
por: Souza, Ashley A., et al.
Publicado: (2020)

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
por: Amanat, Fatima, et al.
Publicado: (2021)

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
por: Li, Tingting, et al.
Publicado: (2021)

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics
por: Zhao, Shaojuan, et al.
Publicado: (2021)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

An NTD supersite of attack
por: Lok, Shee-Mei
Publicado: (2021)

An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation
por: Schoof, Michael, et al.
Publicado: (2020)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
por: Montgomerie, Isabelle, et al.
Publicado: (2023)

A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
por: Gai, Junwei, et al.
Publicado: (2021)

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants
por: Wang, Lingshu, et al.
Publicado: (2021)

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
por: Kombe Kombe, Arnaud John, et al.
Publicado: (2021)

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
por: Lee, Sua, et al.
Publicado: (2021)

A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues
por: Yi, Chunyan, et al.
Publicado: (2022)

Potent neutralizing monoclonal antibodies against Ebola virus infection
por: Zhang, Qi, et al.
Publicado: (2016)

Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2
por: Song, Deyong, et al.
Publicado: (2021)

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
por: Rouet, Romain, et al.
Publicado: (2021)

Stigma: The Stealth Weapon of the NTD
por: Hotez, Peter J.
Publicado: (2008)

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2022)

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020)

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
por: Hurlburt, Nicholas K., et al.
Publicado: (2020)

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
por: Hurlburt, Nicholas K., et al.
Publicado: (2020)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
por: Takeshita, Masaru, et al.
Publicado: (2022)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
por: Chang, Matthew R., et al.
Publicado: (2022)

Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022)

Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
por: Yang, Xuehua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlt9pdr5l7ntpnio4r49v26pvn